Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 202515
Company: HOSPIRA INC
Company: HOSPIRA INC
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
MORPHINE SULFATE | MORPHINE SULFATE | 2MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
MORPHINE SULFATE | MORPHINE SULFATE | 4MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | No |
MORPHINE SULFATE | MORPHINE SULFATE | 8MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | No |
MORPHINE SULFATE | MORPHINE SULFATE | 10MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | No |
MORPHINE SULFATE | MORPHINE SULFATE | 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
MORPHINE SULFATE | MORPHINE SULFATE | 50MG/ML | INJECTABLE;INJECTION | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
11/14/2011 | ORIG-1 | Approval | Type 7 - Drug Already Marketed without Approved NDA | STANDARD |
Label (PDF)
Letter (PDF) Review Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202515Orig1s000Lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202515s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202515_morphine_sulfate_toc.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202515Orig1s000SumR.pdf |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
12/15/2023 | SUPPL-37 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202515s037lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/202515Orig1s037ltr.pdf | |
04/28/2022 | SUPPL-33 | Labeling-Package Insert, Labeling-Container/Carton Labels |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202515Orig1s033lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/202515Orig1s033ltr.pdf | |
04/29/2021 | SUPPL-25 | Efficacy-New Dosing Regimen |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202515s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/202515Orig1s025ltr.pdf | |
10/07/2019 | SUPPL-17 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202515s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/202515Orig1s017ltr.pdf | |
08/17/2020 | SUPPL-7 | Manufacturing (CMC)-Control |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202515Orig1s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/202515Orig1s007ltr.pdf | |
12/16/2016 | SUPPL-6 | Labeling-Package Insert, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202515s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202515Orig1s006ltr.pdf | |
08/14/2013 | SUPPL-3 | Manufacturing (CMC) |
Label is not available on this site. |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
12/15/2023 | SUPPL-37 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202515s037lbl.pdf | |
04/28/2022 | SUPPL-33 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202515Orig1s033lbl.pdf | |
04/28/2022 | SUPPL-33 | Labeling-Container/Carton Labels | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202515Orig1s033lbl.pdf | |
04/29/2021 | SUPPL-25 | Efficacy-New Dosing Regimen | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202515s025lbl.pdf | |
08/17/2020 | SUPPL-7 | Manufacturing (CMC)-Control | Label (PDF) | This supplement type does not usually require new labeling. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202515Orig1s007lbl.pdf |
10/07/2019 | SUPPL-17 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202515s017lbl.pdf | |
12/16/2016 | SUPPL-6 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202515s006lbl.pdf | |
12/16/2016 | SUPPL-6 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202515s006lbl.pdf | |
11/14/2011 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202515Orig1s000Lbl.pdf |
MORPHINE SULFATE
INJECTABLE;INJECTION; 2MG/ML
TE Code = AP
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
MORPHINE SULFATE | MORPHINE SULFATE | 2MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 211452 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 2MG/ML | INJECTABLE;INJECTION | Prescription | Yes | AP | 202515 | HOSPIRA INC |
INJECTABLE;INJECTION; 4MG/ML
TE Code = AP
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
MORPHINE SULFATE | MORPHINE SULFATE | 4MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 205758 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 4MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 211452 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 4MG/ML | INJECTABLE;INJECTION | Prescription | Yes | AP | 202515 | HOSPIRA INC |
INJECTABLE;INJECTION; 8MG/ML
TE Code = AP
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
MORPHINE SULFATE | MORPHINE SULFATE | 8MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 205758 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 8MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 211452 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 8MG/ML | INJECTABLE;INJECTION | Prescription | Yes | AP | 202515 | HOSPIRA INC |
INJECTABLE;INJECTION; 10MG/ML
TE Code = AP
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
INFUMORPH | MORPHINE SULFATE | 10MG/ML | INJECTABLE;INJECTION | Prescription | Yes | AP | 018565 | HIKMA |
MITIGO | MORPHINE SULFATE | 10MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 204393 | PIRAMAL CRITICAL |
MORPHINE SULFATE | MORPHINE SULFATE | 10MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 205758 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 10MG/ML | INJECTABLE;INJECTION | Prescription | No | AP | 211452 | HIKMA |
MORPHINE SULFATE | MORPHINE SULFATE | 10MG/ML | INJECTABLE;INJECTION | Prescription | Yes | AP | 202515 | HOSPIRA INC |